journal
MENU ▼
Read by QxMD icon Read
search

Pulmonary Pharmacology & Therapeutics

journal
https://www.readbyqxmd.com/read/28093225/il-4r-suppresses-airway-inflammation-in-bronchial-asthma-by-inhibiting-the-il-4-stat6-pathway
#1
Ying Liu, Hui Zhang, Ran Ni, Wen-Qing Jia, Yuan-Yuan Wang
OBJECTIVE: This study aims to explore the mechanisms of how IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4/STAT6 pathway. METHODS: A total of 27 BALB/c male mice were selected and divided into control, asthma and IL-4R groups. Ovalbumin-induced mouse asthma model was established. Maximal pulmonary resistance was recorded. Hematoxylin and eosin (HE) and periodic acid Schiff (PAS) staining were conducted to observe the pathological changes in lung tissue...
January 13, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28093224/beta-2-adrenoreceptor-polymorphism-at-position-16-determines-the-clinical-severity-of-chronic-obstructive-pulmonary-disease
#2
Justyna Emeryk-Maksymiuk, Andrzej Emeryk, Paweł Krawczyk, Kamila Wojas-Krawczyk, Janusz Milanowski
The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. In contrast, the results of the studies analysing the effect of ADRB2 polymorphisms on the response to beta-2-adrenoreceptor agonists in chronic obstructive pulmonary disease (COPD) patients are sparse and inconclusive. The aim of this research was to verify if p.Arg16Gly (c.46A > G) and p.Gly27Glu (c...
January 13, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28087469/tofacitinib-ameliorates-inflammation-in-a-rat-model-of-airway-neutrophilia-induced-by-inhaled-lps
#3
Elena Calama, Isabel Ramis, Anna Domènech, Cristina Carreño, Jorge De Alba, Neus Prats, Montserrat Miralpeix
BACKGROUND: and purpose: The Janus Kinase (JAK) family mediates the cytokine receptor-induced signalling pathways involved in inflammatory processes. The activation of the signal transducers and activators of transcription (STATs) by JAK kinases is a key point in these pathways. Four JAK proteins, JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2) associate with the intracellular domains of surface cytokine receptors are phosphorylating STATs and modulating gene expression. The aim of this study was to explore the role of JAK inhibition in an acute model of inhaled lipopolysaccharide (LPS)-induced airway inflammation in rats through evaluating the effects of tofacitinib, a marketed pan-JAK inhibitor...
January 10, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28089891/which-treatment-for-obstructive-airway-disease-the-inhaled-bronchodilators
#4
LETTER
Fabio Perrotta, Filomena Mazzeo, Francesco Saverio Cerqua
No abstract text is available yet for this article.
January 9, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28065679/acute-cardiovascular-safety-of-two-formulations-of-beclometasone-dipropionate-formoterol-fumarate-in-copd-patients-a-single-dose-randomised-placebo-controlled-crossover-study
#5
Dave Singh, Giorgia Ciurlia, Annalisa Piccinno, Annamaria Muraro, Maria Bocchi, Mario Scuri
INTRODUCTION: An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some years for the management of asthma and chronic obstructive pulmonary disease (COPD). A dry powder inhaler (DPI) formulation of extrafine BDP/FF is now also available. This study evaluated the cardiovascular safety of BDP/FF DPI in comparison to BDP/FF pMDI and placebo. METHODS: Single-dose, partially-blind, randomised, placebo-controlled, 5-period crossover study...
January 5, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28062322/mir-23b-controls-tgf-%C3%AE-1-induced-airway-smooth-muscle-cell-proliferation-via-direct-targeting-of-smad3
#6
Ming Chen, Jianting Shi, Wei Zhang, Linjie Huang, Xiaoling Lin, Zhiqiang Lv, Wei Zhang, Ruiyun Liang, Shanping Jiang
BACKGROUND: MicroRNAs are small yet versatile gene tuners that regulate a variety of cellular processes, including cell growth and proliferation. Here we report that miR-23b inhibited airway smooth muscle cells (ASMCs) proliferation through directly targeting of Smad3. METHODS: We obtained ASMCs by laser capture microdissection of normal and asthmatic mice lung tissues. Mice ASMCs were cultured and induced by TGF-β1. The implication between TGF-β1 and miR-23b in ASMCs were detected by RT-PCR...
January 3, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28039077/pharmacokinetics-of-tiotropium-administered-by-respimat-%C3%A2-in-asthma-patients-analysis-of-pooled-data-from-phase-ii-and-iii-clinical-trials
#7
Ashish Sharma, Huib A M Kerstjens, René Aalbers, Petra Moroni-Zentgraf, Benjamin Weber, Ronald Dahl
Tiotropium is a long-acting inhaled antimuscarinic bronchodilator that has recently received marketing authorization for the indication of asthma with dose delivery via the Respimat(®) inhaler, in addition to its widely established role in the management of chronic obstructive pulmonary disease (COPD). This report presents a combined analysis of tiotropium plasma and urine pharmacokinetics at steady state from 8 Phase II/III clinical trials in asthma and delineates the effects of patient characteristics on systemic exposure based on the parameters fe0-24,ss (fraction of dose excreted unchanged in urine over 24 h post-dose at steady-state) and dose-normalized AUCtau,ss and Cmax,ss...
December 27, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27979760/diagnostic-and-prognostic-challenges-in-idiopathic-pulmonary-fibrosis-a-patient-q-and-a-approach
#8
REVIEW
Argyris Tzouvelekis, Vasilios Tzilas, Spyridon Papiris, Vassilis Aidinis, Demosthenes Bouros
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology that leads to death nearly half of the patients within 3-3.5 years. The past 15 years, the scientific community has made tremendous progress towards standardized diagnostic and prognostic algorithms that led to the generation of the 2011 ATS/ERS/JRS/ALAT guidelines. The latest guidelines provided us with fundamental diagnostic algorithms that set the diagnosis in the majority of cases; however, they leave a significant minority of patients without diagnostic and most importantly therapeutic umbrella...
December 12, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27940287/fast-onset-of-action-of-glycopyrronium-compared-with-tiotropium-in-patients-with-moderate-to-severe-copd-a-randomised-multicentre-crossover-trial
#9
Henrik Watz, Claudia Mailänder, Christoph May, Monika Baier, Anne-Marie Kirsten
BACKGROUND: Long-acting bronchodilators, including anticholinergics glycopyrronium and tiotropium, are central to symptomatic management of chronic obstructive pulmonary disease (COPD). In patients with moderate to severe COPD, glycopyrronium has demonstrated comparable efficacy to open-label and single-blinded tiotropium, but with faster onset of bronchodilation. The FAST study assessed the efficacy of glycopyrronium compared with tiotropium in serial spirometry and body plethysmography assessments to further characterize the earlier onset of action associated with glycopyrronium...
December 8, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888045/effects-of-tiotropium-on-lung-function-in-current-smokers-and-never-smokers-with-bronchial-asthma
#10
Makoto Yoshida, Yasuko Kaneko, Akiko Ishimatsu, Masashi Komori, Tomoaki Iwanaga, Hiromasa Inoue
The effects of tiotropium, an inhaled long-acting muscarinic antagonist, on lung function were investigated in current smokers and nonsmokers with asthma treated with inhaled corticosteroids (ICSs) and other asthma controllers: inhaled long-acting β2 agonists, leukotriene receptor antagonists, and/or theophylline. We conducted a double-blind, placebo-controlled study of an inhaled single dose of tiotropium in 9 asthmatics currently smoking and 9 asthmatics who have never smoked in a crossover manner. Lung function was measured before and 1, 3, and 24 h after inhalation of 18 μg of tiotropium or a placebo...
November 22, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27864038/a-systematic-review-with-meta-analysis-of-fluticasone-furoate-vilanterol-combination-for-the-treatment-of-stable-copd
#11
Gustavo J Rodrigo, Hugo Neffen
BACKGROUND: Current guidelines recommend the use of inhaled corticosteroids/long-acting beta2-agonists as first-line therapy for COPD patients at risk for acute exacerbations and/or severe airflow limitation. This systematic review assesses available evidence on the efficacy and safety of fluticasone furoate/vilanterol (FF/VI) combination versus each alone, for the treatment of patients with severe to very severe stable COPD. METHODS: Randomized, placebo-controlled trials of >8 weeks of duration were included...
November 15, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27816773/the-soluble-guanylyl-cyclase-activator-bay-60-2770-inhibits-murine-allergic-airways-inflammation-and-human-eosinophil-chemotaxis
#12
Lineu Baldissera, Dalize M Squebola-Cola, Marina C Calixto, Ana P Lima-Barbosa, André L Rennó, Gabriel F Anhê, Antonio Condino-Neto, Gilberto De Nucci, Edson Antunes
OBJECTIVES: Activators of soluble guanylyl cyclase (sGC) act preferentially in conditions of enzyme oxidation or haem group removal. This study was designed to investigate the effects of the sGC activator BAY 60-2770 in murine airways inflammation and human eosinophil chemotaxis. METHODS: C57Bl/6 mice treated or not with BAY 60-2770 (1 mg/kg/day, 14 days) were intranasally challenged with ovalbumin (OVA). At 48 h, bronchoalveolar lavage fluid (BALF) was performed, and circulating blood, bone marrow and lungs were obtained...
November 2, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27816772/biochemical-and-functional-characterization-of-glycosaminoglycans-released-from-degranulating-rat-peritoneal-mast-cells-insights-into-the-physiological-role-of-endogenous-heparin
#13
Rebecca Lever, Amir Smailbegovic, Yanira Riffo-Vasquez, Elaine Gray, John Hogwood, Stephen M Francis, Neville V Richardson, Clive P Page, Barbara Mulloy
The properties of commercially prepared heparin as an anticoagulant and antithrombotic agent in medicine are better understood than is the physiological role of heparin in its native form, where it is uniquely found in the secretory granules of mast cells. In the present study we have isolated and characterised the glycosaminoglycans (GAGs) released from degranulating rat peritoneal mast cells. Analysis of the GAGs by NMR spectroscopy showed the presence of both heparin and the galactosaminoglycan dermatan sulphate; heparinase digestion profiles and measurements of anticoagulant activity were consistent with this finding...
November 2, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27651324/lack-of-efficacy-of-nebulized-magnesium-sulfate-in-treating-adult-asthma-a-meta-analysis-of-randomized-controlled-trials
#14
REVIEW
Zhou-Gui Ling, Yan-Bin Wu, Jin-Liang Kong, Zhen-Ming Tang, Wei Liu, Yi-Qiang Chen
BACKGROUND: Nebulized magnesium sulfate (MgSO4) has been used to treat asthma, but the efficacy remains controversial. We aimed to comprehensively review the efficacy of nebulized MgSO4 in treating adult patients with asthma. METHODS: PubMed, Embase, and Cochrane Library were searched for relevant studies published up to July 18, 2016. Randomized controlled trials (RCTs) were included if adult patients with acute or stable asthma had been treated with nebulized MgSO4 compared with placebo or another bronchodilator...
December 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27538683/antitussive-effect-of-carcainium-chloride-in-patients-with-chronic-cough-and-idiopathic-interstitial-pneumonias-a-pilot-study
#15
Federico Lavorini, Domenico Spina, Michael J Walker, Lui Franciosi, Clive P Page, Giovanni A Fontana
BACKGROUND: Cough is a common presenting symptom in patients with idiopathic interstitial pneumonia (IIP); it is often disabling, and lacks effective treatment. Studies in animals suggest that carcainium chloride, a quaternary derivative of the local anesthetic lidocaine, is able to inhibit experimentally induced cough by a mechanism of action distinct from that of lidocaine. OBJECTIVE: To determine the effectiveness of aerosolised carcainium chloride (VRP700) in controlling cough in patients with IIP...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27506415/short-term-versus-longer-duration-of-glucocorticoid-therapy-for-exacerbations-of-chronic-obstructive-pulmonary-disease
#16
REVIEW
Zhao Ma, Wei Zhang
BACKGROUND: Systemic glucocorticoid has been shown to improve the outcome of acute exacerbation of chronic obstructive pulmonary disease (COPD). However, the optimal duration remains controversial. OBJECTIVES: To investigate whether a short-term (seven days or fewer) systemic glucocorticoid treatment in patients with COPD exacerbation is non inferior to longer duration (more than seven days) treatment in clinical outcome. METHODS: We searched PubMed, EMBASE, CENTRAL databases, China Clinical Trials, CNKI, The Chinese biomedical literature database (CBM) and wanfang database to identify randomized controlled trials using systemic glucocorticoid in COPD...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27481628/pirfenidone-nintedanib-and-n-acetylcysteine-for-the-treatment-of-idiopathic-pulmonary-fibrosis-a-systematic-review-and-meta-analysis
#17
Paola Rogliani, Luigino Calzetta, Francesco Cavalli, Maria Gabriella Matera, Mario Cazzola
BACKGROUND: The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year. Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received only a conditional recommendation for use and, thus, to date no drugs are strongly recommended for IPF. The aim of this study was to assess the effectiveness and safety of the currently approved drugs for IPF and N-acetylcysteine (NAC), the most debated drug in the last update of guidelines for IPF treatment...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27470682/evaluation-of-adiponectin-profile-in-italian-patients-affected-by-obstructive-sleep-apnea-syndrome
#18
Donato Lacedonia, Ersilia Nigro, Maria Gabriella Matera, Olga Scudiero, Maria Ludovica Monaco, Rita Polito, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro, Gennaro Mazzarella, Andrea Bianco, Aurora Daniele
Obstructive sleep apnea syndrome (OSAS) is a common breathing disorder; obesity represents a major risk factor for the development and progression of OSAS although obese patients do not necessarily suffer from OSAS. Adipose tissue communicates with lung in both physiologic and pathologic conditions through the production of adipokines, hormones active in metabolic and inflammatory processes. To explore the extent to which Acrp30 impacts on pathophysiology of OSAS and whether these proteins could be considered as targets for both diagnosis and therapy through enzyme-linked immunosorbent assay, western blotting analysis and fast protein liquid chromatography we have analyzed total levels as well as oligomer distribution in OSAS patients...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27470681/efficacy-of-tranexamic-acid-in-haemoptysis-a-randomized-controlled-pilot-study
#19
Balaji Laxminarayanshetty Bellam, Deba Prasad Dhibar, Vikas Suri, Navneet Sharma, Subhash Chander Varma, Samir Malhotra, Ashish Bhalla
BACK GROUND: Haemoptysis is a life threatening condition irrespective of aetiology. Tranexamic acid (TA), a potent anti-fibrinolytic agent, has been shown to control bleeding, decrease transfusion requirement in knee & hip arthroplasty, coronary artery bypass grafting and heavy menstrual bleeding. TA also has mortality benefit in bleeding from surgical and trauma patients. But the studies, regarding efficacy and safety of TA in controlling haemoptysis are conflicting. METHOD: In this single blinded, prospective study, total 66 patients with sub-massive haemoptysis were randomized into treatment (T) and placebo control (C) groups...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27470680/transitioning-from-parenteral-to-inhaled-prostacyclin-therapy-in-pulmonary-arterial-hypertension
#20
Ali Ataya, Angelina Somoracki, Jessica Cope, Hassan Alnuaimat
BACKGROUND: Parenteral prostacyclin therapy for PAH has allowed for improvements in functional status, quality of life and mortality. Parenteral therapies however carry an increased risk of line-associated complications. Inhaled prostacyclins are an attractive alternative therapy; however, limited data exists supporting the safety and outcomes after transition. METHODS: We describe a retrospective observational analysis of adults with PAH who were transitioned from a parenteral prostacyclin to inhaled treprostinil at our institution...
October 2016: Pulmonary Pharmacology & Therapeutics
journal
journal
32865
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"